A novel combined prognostic nutritional index and aspartate aminotransferase-to-platelet ratio index-based score can predict the survival of patients with hepatocellular carcinoma who undergo hepatic resection
- PMID: 35066743
- DOI: 10.1007/s00595-021-02440-0
A novel combined prognostic nutritional index and aspartate aminotransferase-to-platelet ratio index-based score can predict the survival of patients with hepatocellular carcinoma who undergo hepatic resection
Abstract
Purpose: Inflammation-, nutrition-, and liver fibrosis-related markers are recognized as prognostic for hepatocellular carcinoma (HCC) patients. This study, therefore, assessed the preoperative prognostic utility of the combination of these markers in patients with HCC.
Methods: This single-center retrospective study included patients who underwent hepatic resection for HCC between 2004 and 2017. A total of 454 patients were divided into training (n = 334) and validation (n = 120) cohorts by random sampling. The predictive impact on surgical outcomes was evaluated using receiver operating characteristic (ROC) curves of these prognostic values in the training cohort.
Results: The prognostic nutritional index (PNI) and aspartate aminotransferase-to-platelet ratio index (APRI) were the strongest diagnostic values (areas under the ROC curves: 0.627 and 0.646, respectively). A scoring system (over 0-2 points) was developed using optimal cutoff values (for PNI < 46.5 scored as 1 point; for APRI > 0.98 scored as 1 point). An increased PNI-APRI score was an independent prognostic factor for both the overall and disease-free survival in HCC patients. Finally, the clinical feasibility of the PNI-APRI score was confirmed in the validation cohort.
Conclusions: The PNI-APRI score is a useful marker for predicting surgical outcomes of HCC patients.
Keywords: Aspartate aminotransferase-to-platelet ratio index; Hepatocellular carcinoma; Prognosis; Prognostic nutritional index.
© 2021. The Author(s) under exclusive licence to Springer Nature Singapore Pte Ltd.
References
-
- Forner A, Reig M, Bruix J. Hepatocellular carcinoma. The Lancet. 2018;391(10127):1301–14. - DOI
-
- Itoh S, Morita K, Ueda S, Sugimachi K, Yamashita Y, Gion T, et al. Long-term results of hepatic resection combined with intraoperative local ablation therapy for patients with multinodular hepatocellular carcinomas. Ann Surg Oncol. 2009;16(12):3299–307. - DOI
-
- Roayaie S, Jibara G, Tabrizian P, Park JW, Yang J, Yan L, et al. The role of hepatic resection in the treatment of hepatocellular cancer. Hepatology. 2015;62(2):440–51. - DOI
-
- Harimoto N, Yoshizumi T, Shimagaki T, Nagatsu A, Motomura T, Harada N, et al. Inflammation-based prognostic score in patients with living donor liver transplantation for hepatocellular carcinoma. Anticancer Res. 2016;36(10):5537–42. - DOI
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical